Program
Tenecteplase
Also written as “tenecteplase”, “rhTNK-tPA” and “GNR-060”.
Its studies are mostly in Myocardial Infarction · Ischemic Stroke · ST Elevation Myocardial Infarction · Stroke · Heart Arrest, led by 4 companies.
Drug pageTenecteplase: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 81 open or running | phase 4since Sep 9, 2005 | Sep 7, 2005 | Oct 2, 2027phase 3 · NCT07361302 |
| Hoffmann-La Rocheits history only | 50 open or running | phase 3since Nov 2, 2006 | Nov 2, 2006 | none ahead |
| CSPC Pharmaceutical Groupits history only | 21 open or running | phase 4since Jun 12, 2016 | Jun 12, 2016 | Sep 30, 2027phase 3 · NCT07201688 |
| AO GENERIUMits history only | 10 open or running | phase 3since Oct 26, 2022 | Oct 26, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2005First studies: 2 phase 3 studiesFirst studyNCT00148460, NCT00157261
- Sep 9, 2005Phase 4 study in Myocardial InfarctionNCT00168792 · 1,671 enrolled · United States, Austria, Belgium and more
- Feb 15, 2008Phase 3 study in Myocardial InfarctionNCT00623623 · 1,899 enrolled · Austria, Belgium, Brazil and more
- Jul 2, 20142 phase 3 studies in Myocardial InfarctionNCT02182011, NCT02181985
- Jun 4, 2021Phase 3 study in StrokeNCT04915729 · 1,489 enrolled · China
- Jan 14, 2026Phase 3 study in Ischemic StrokeNCT07361302 · 1,325 planned · Argentina, Australia, Bulgaria and more
Ahead
- Oct 2, 2027Primary completion: phase 3 study in Ischemic StrokeNCT07361302
TargetBeta
“Tissue-type plasminogen activator exogenous protein”ChEMBL 37, by rule
Studies
All 8 Boehringer Ingelheim leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07361302Ischemic Stroke · Argentina, Australia, Bulgaria and more | 3 | Recruiting | Oct 2, 2027 | 1,325 |
| NCT04915729Stroke · China | 3 | Completed | Oct 8, 2023 | 1,489 |
| NCT02182011Myocardial Infarction | 3 | Completed | Jun 2001 | 49 |
| NCT02181985Myocardial Infarction | 3 | Completed | Apr 2001 | 5,989 |
| NCT00623623Myocardial Infarction · Austria, Belgium, Brazil and more | 3 | Completed | Sep 1, 2012 | 1,899 |
| NCT00168792Myocardial Infarction · United States, Austria, Belgium and more | 4 | Terminated | Jul 2006 | 1,671 |
| NCT00157261Heart Arrest · Austria, Belgium, France and more | 3 | Terminated | Jun 2006 | 1,050 |
| NCT00148460Myocardial Infarction · China, Hong Kong, Korea, Republic of | 3 | Completed | 270 |
How it is read
Names in the registry
- “tenecteplase”, 6 entries
- “Tenecteplase”, 5 entries
- “rhTNK-tPA”, 2 entries
- “GNR-060”, 1 entry
- “Full dose TNK-tPA”, 1 entry
Conditions, from the studies’ own filings
- Myocardial Infarction, 5 studies
- Ischemic Stroke, 2 studies
- ST Elevation Myocardial Infarction, 2 studies
- Stroke, 1 study
- Heart Arrest, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.